MYCOVERSE India Initiative: Consciousness, Mushrooms & Human Development

MYCOVERSE India Initiative: Consciousness, Mushrooms & Human Development

A Transdisciplinary Research Program for the UN Sustainable Development Goals

We are seeking an Indian university partner. If your institution is interested, please contact us at the end of this page.

Why This Research Matters

A global renaissance in psychedelic research is underway. Clinical trials at Johns Hopkins, Imperial College London, and University Hospital Basel have demonstrated that psilocybin-assisted therapy produces significant improvements in depression, anxiety, and PTSD. But this field carries a structural flaw: almost all studies use isolated, synthetic psilocybin. The Western pharmaceutical model threatens to make these therapies inaccessible to the majority of the world’s population. A single session in the US currently costs between 1,000 and 5,000 US dollars.

The MYCOVERSE India Initiative addresses this flaw at its root. It asks the question no Western research program can currently answer: Does the whole psilocybin mushroom, with its complete natural alkaloid profile, produce different, stronger, or longer-lasting effects than isolated synthetic psilocybin? And can it do so at a fraction of the cost?

This project emerged directly from the research program documented in Mystical Medicine: The Healing Reality of Psilocybin, Near-Death, and Dying (Pawlik 2026), which presents the first systematic synthesis of psilocybin research, near-death experiences, and mystical dying phenomena, and identifies accessible whole-mushroom therapy as one of the most urgent ethical imperatives in global health.

India’s Unique Legal Position

India is currently the only country in the world where this research can be conducted legally and methodologically correctly. Two landmark High Court rulings have created this unique framework:

Karnataka High Court (2013): Requires precise quantification of psilocybin content for prosecution – establishing that the mushroom as a biological organism is distinct from the isolated chemical.

Kerala High Court (2025): Confirmed explicitly that psilocybin-containing mushrooms are natural organisms and not „narcotic mixtures“ under the NDPS Act.

For a licensed university research program, this means: an application for an NDPS research license can be argued based on controlled, quantified psilocybin content in whole mushrooms – precisely what the MYCOVERSE standardization methodology provides. No other jurisdiction currently offers this combination of legal clarity and research freedom.

The Research Program: Three Stages

The program follows a scientifically rigorous three-stage progression:

Stage A – Standardization (Months 1–12)
Can whole mushrooms be produced with reproducible, verified alkaloid profiles? This stage identifies local Indian Psilocybe species, develops cultivation protocols with less than 10% variance in active content, and applies for the NDPS research license. It begins immediately with fully legal medicinal mushroom research – Lion’s Mane and Reishi – to build the institutional relationship and regulatory track record the psilocybin phases require.

Stage B – Whole Mushroom Pilot Trial (Months 13–30)
Does the whole mushroom, combined with meditation, produce therapeutic and learning effects? A two-arm double-blind randomized controlled trial with 60 participants compares standardized whole mushrooms plus an eight-week meditation program against a placebo plus the identical program. This is the world’s first clinical trial of whole Psilocybe mushrooms.

Stage C – Full Comparison Trial (Months 31–54)
Does the whole mushroom outperform full-spectrum extract and isolated psilocybin? A three-arm trial with 120 participants compares whole mushroom versus full-spectrum extract versus isolated psilocybin – the definitive entourage effect study that Western pharmaceutical models cannot conduct because they begin with the isolate.

UN Sustainable Development Goals

The program directly addresses six SDGs:

SDG 3 – Good Health and Well-being: Improving depression and burnout through psilocybin-assisted group therapy.

SDG 4 – Quality Education: Increasing cognitive flexibility and openness to lifelong learning.

SDG 10 – Reduced Inequalities: Reducing costs by using whole mushrooms instead of expensive pharmaceutical extracts.

SDG 12 – Responsible Consumption: Promoting environmental awareness through nature-relatedness.

SDG 15 – Life on Land: Documenting and protecting India’s mycological biodiversity.

SDG 16 – Peace, Justice and Strong Institutions: Reducing ideological rigidity and promoting empathy and prosociality.

Budget Overview

The estimated total budget for the six-year program is 1,687,600 EUR, distributed across four phases: standardization and medicinal mushroom research (179,300 EUR), Stage B pilot trial (541,200 EUR), Stage C comparison trial (617,100 EUR), and scaling (350,000 EUR).

Ethical Framework

The project follows strict ethical principles: full informed consent, medical oversight and standardized exclusion criteria, integration of Indian traditions as equal partners, no patents on natural preparations, and open-access publication of all results. The guiding principle is Vasudeva Kutumbkam – we are one human family.

Partner Roles

The MYCOVERSE Foundation provides ethics oversight, methodology transfer, and an international network. gluckspilze.com provides technical expertise, a culture bank of 1,500 mushroom species, and team training. The Global Harmony Association provides cultural bridge-building and a Vedic research framework.

We are actively seeking an Indian university partner to take scientific leadership, hold the research license, and lead local implementation. This is the role that makes the research possible.

We Are Looking For You

If you are connected to an Indian university or research institution with an interest in consciousness research, mycology, meditation science, or psychedelic medicine – or if you know someone who is – we would welcome the conversation.

This is a historic scientific opportunity. India’s legal framework, its spiritual traditions, and its mycological biodiversity meet the most pressing question in global psychedelic science. We begin with whole mushrooms because it is the path India legally permits and the world scientifically requires.

Contact:
Mag. Dr. phil. Lucas Pawlik
Ethics Director, MYCOVERSE Foundation
lucas.pawlik@mycoverse-foundation.org
mycoverse-foundation.org

Reference for citation:
Pawlik, L. (2026). MYCOVERSE India Initiative: Consciousness, Mushrooms & Human Development. Version 1.1. MYCOVERSE Foundation, Vaduz. Available at: mycoverse-foundation.org